An anonymous director reports

HLS THERAPEUTICS TO HOST Q1 2025 FINANCIAL RESULTS CONFERENCE CALL

HLS Therapeutics Inc. will release its first quarter 2025 financial results on Thursday, May 8, 2025. The company will hold a conference call that same day at 8:30 a.m. ET to discuss its results. The call will be co-hosted by Craig Millian, chief executive officer; John Hanna, chief financial officer; and Brian Walsh, chief commercial officer. Slides to accompany management's prepared remarks will be available to view via the webcast.

Date:  Thursday, May 8, 2025

Time:  8:30 a.m. ET

Traditional dial-in numbers:  1-888-699-1199 or 1-416-945-7677

Conference ID:  41562

Taped replay:  1-888-660-6345 or 1-646-517-4150

Replay code:  41562 followed by the pound key

The taped replay will be available for 14 days, and the archived webcast will be available for 365 days.

A link to the live audio webcast of the conference call will be available on the investors section of HLS Therapeutics' website. Please connect at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to hear the webcast.

About HLS Therapeutics Inc.

Formed in 2015, HLS is a pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. HLS's focus is on products that address unmet needs in the treatment of psychiatric disorders and cardiovascular diseases. HLS's management team comprises seasoned pharmaceutical executives with a strong record of success in these therapeutic areas and at managing products in each of these life cycle stages.